Claims for Patent: 8,206,735

Summary for Patent: 8,206,735

Title:	Pharmaceutical compositions for sustained release delivery of peptides
Abstract:	The present invention provides methods of forming a solid, biodegradable implant in-situ in a body by administering a liquid pharmaceutical composition comprising an effective amount of a biocompatible, water-insoluble, biodegradable polymer and an effective amount of a therapeutic peptide covalently modified with one or more lipophilic or amphiphilic moieties, which are dissolved or dispersed in a biocompatible, water-soluble organic solvent. This invention also provides related compositions and methods.
Inventor(s):	Li; Yuhua (Newark, DE), Chien; Benjamin (Newark, DE)
Assignee:	Foresee Pharmaceuticals, LLC (Newark, DE)
Application Number:	11/827,260
Patent Claims:	1. A liquid polymeric pharmaceutical composition for controlled release of a therapeutic polypeptide, comprising effective amounts of: (a) a pharmaceutically acceptable, water insoluble, biodegradable polymer selected from the group consisting of a polylactide, a polyglycolide, a polycaprolactone, a polydioxanone, a polycarbonate, a polyhydroxybutyrate, a polyalkylene oxalate, a polyanhydride, a polyamide, a polyesteramide, a polyurethane, a polyacetal, a polyorthocarbonate, a polyphosphazene, a polyhydroxyvalerate, a polyalkylene succinate, and a polyorthoester, and copolymers, block copolymers, branched copolymers, terpolymers and combinations and mixtures thereof; (b) a pharmaceutically acceptable organic solvent which solubilizes the biodegradable polymer; and (c) a therapeutic polypeptide conjugated with one or more lipophilic moieties, wherein the composition is in the form of an injectable viscous liquid and is capable of forming a controlled release implant by dissipation or dispersion of the organic solvent within a subject's body; and wherein the composition has a higher in vitro stability and a lower initial burst release than the composition would were the therapeutic polypeptide not conjugated to the lipophilic moieties. 2. A method for forming the liquid polymeric pharmaceutical composition of claim 1, comprising the steps of (a) dissolving a pharmaceutically acceptable, water-insoluble, biodegradable polymer--selected from the group consisting of a polylactide, a polyglycolide, a polycaprolactone, a polydioxanone, a polycarbonate, a polyhydroxybutyrate, a polyalkylene oxalate, a polyanhydride, a polyamide, a polyesteramide, a polyurethane, a polyacetal, a polyorthocarbonate, a polyphosphazene, a polyhydroxyvalerate, a polyalkylene succinate, and a polyorthoester, and copolymers, block copolymers, branched copolymers, terpolymers and combinations and mixtures thereof, in a pharmaceutically acceptable organic solvent to form a polymer solution; and (b) admixing the polymer solution with an effective amount of a therapeutic polypeptide conjugated with one or more lipophilic moieties to form said liquid polymeric pharmaceutical composition. 3. A method for forming a solid, biodegradable implant in-situ for sustained delivery of a therapeutic polypeptide comprising administering the liquid polymeric pharmaceutical composition of claim 1 into an implant site within a subject's body. 4. A method for forming a solid, biodegradable implant in-situ for sustained delivery of a therapeutic polypeptide comprising (a) forming a liquid polymeric pharmaceutical composition according to the method of claim 2, and (b) administering the resulting composition into an implant site within a subject's body. 5. The composition of claim 1, wherein the polypeptide and the lipophilic moiety or moieties are covalently conjugated. 6. The composition of claim 1, wherein the polypeptide and the lipophilic moiety or moieties are covalently conjugated through a spacer, a bridge or a linker group. 7. The composition of claim 1, wherein the polypeptide is selected from the group consisting of oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), prolactin, luteinizing hormone, luteinizing hormone releasing hormone (LHRH), an LHRH agonist, an LHRH antagonist, a growth hormone, growth hormone releasing factor, insulin, erythropoietin, somatostatin, glucagon, interleukin, interferon-alpha, interferon-beta, interferon-gamma, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, an enkephalin, an endorphin, an angiotensin, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), parathyroid hormone (PTH), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), heparinase, vascular endothelial growth factor (VEG-F), bone morphogenic protein (BMP), hANP, glucagon-like peptide (GLP-1), exenatide, peptide YY (PYY), Ghrelin, renin, bradykinin, a bacitracin, a polymyxin, a colistin, tyrocidine, a gramicidin, a cyclosporin, an enzyme, a cytokine, an antibody, a vaccine, an antibiotic, a glycoprotein, follicle stimulating hormone, kyotorphin, taftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor, serum thymic factor, a colony stimulating factor, motilin, bombesin, dinorphin, neurotensin, cerulein, urokinase, kallikrein, a substance P analogue, a substance P antagonist, angiotensin II, blood coagulation factors VII and IX, lysozyme, a gramicidine, melanocyte stimulating hormone, thyroid hormone releasing hormone, thyroid stimulating hormone, pancreozymin, cholecystokinin, human placental lactogen, human chorionic gonadotrophin, protein synthesis stimulating peptide, gastric inhibitory peptide, vasoactive intestinal peptide, and platelet derived growth factor. 8. The composition of claim 1, wherein the polypeptide is selected from the group consisting of ACTH, glucagon, somatotropin, thymosin, a pigmentary hormone, somatomedin, chorionic gonadotropin, a hypothalmic releasing factor, an antidiuretic hormone, thyroid stimulating hormone, biphalin and prolactin. 9. The composition of claim 1, wherein the polypeptide is selected from the group consisting of epidermal growth factor (EGF), an LHRH agonist, an LHRH antagonist, a growth hormone, growth hormone releasing factor, octreotide, interferon-alpha, interferon-beta, interferon-gamma, calcitonin, parathyroid hormone (PTH), glucagon-like peptide (GLP-1), and peptide YY (PYY). 10. The composition of claim 1, wherein the polypeptide is glucagon like peptide 1 (GLP-1). 11. The composition of claim 1, wherein the polypeptide is exendin. 12. The composition of claim 1, wherein the polypeptide is octreotide. 13. The composition of claim 1, wherein the polypeptide is insulin. 14. The composition of claim 1, wherein the lipophilic moiety is selected from the group consisting of C3-39-alkyl, C3-39-alkenyl, C3-39-alkadienyl, tocopherol and steroidal compounds. 15. The composition of claim 14, wherein each of the C3-39-alkyl, C3-39-alkenyl and C3-39-alkadienyl is (i) straight chain or branched, and (ii) saturated, monounsaturated or di-unsaturated. 16. The composition of claim 1, wherein the lipophilic moiety is a lipid. 17. The composition of claim 1, wherein the biodegradable polymer is selected from the group consisting of a polylactic acid and a polyglycolic acid, and copolymers thereof. 18. The composition of claim 1, wherein the organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, propylene carbonate, caprolactam, triacetin, benzyl benzoate, benzyl alcohol, ethyl lactate, glyceryl triacetate, an ester of citric acid, polyethylene glycol, alkoxypolyethylene glycol, polyethylene glycol acetate, or any combination thereof.

Details for Patent 8,206,735

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2026-07-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2026-07-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2026-07-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2026-07-11
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2026-07-11
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		2026-07-11
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2026-07-11